Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Monotherapy and Combinations in Multiple Myeloma
NCT05714839Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jun 2023
- Primary completion
- Aug 2028
- Countries
- 13
01
Overview
A Phase 2 trial of belantamab in multiple myeloma (MM), sponsored by GSK. Started Jun 2023; status: recruiting.
02
Drugs
belantamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05714839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05714839.